Literature DB >> 1579256

Life expectancy in patients attending multiple sclerosis clinics.

A D Sadovnick1, G C Ebers, R W Wilson, D W Paty.   

Abstract

One multiple sclerosis (MS) is diagnosed, important considerations often include life expectancy and the availability of life insurance. We designed a study specifically to examine life expectancy among MS clinic patients and analyzed the data using standard actuarial methods, both including and excluding suicides. The data show that severe MS disability, as measured by an Expanded Disability Status Score (EDSS) of greater than or equal to 7.5, is a major risk factor for death with case fatality ratios for this group of patients approaching 4 times the rate for controls. Conversely, excluding deaths by suicide, case fatality ratios for those with mild and moderate disability (EDSS less than or equal to 7.0) approach 1.4 times and 1.6 times for age- and sex-matched comparison groups. Life tables indicate that the overall life expectancy for MS is only about 6 to 7 years less than that for the "insured" population without MS.

Entities:  

Mesh:

Year:  1992        PMID: 1579256     DOI: 10.1212/wnl.42.5.991

Source DB:  PubMed          Journal:  Neurology        ISSN: 0028-3878            Impact factor:   9.910


  32 in total

Review 1.  Pharmacological treatment of early multiple sclerosis.

Authors:  Olaf Stüve; Jeffrey L Bennett; Bernhard Hemmer; Heinz Wiendl; Michael K Racke; Amit Bar-Or; Wei Hu; Robert Zivadinov; Martin S Weber; Scott S Zamvil; Maria F Pacheco; Til Menge; Hans-Peter Hartung; Bernd C Kieseier; Elliot M Frohman
Journal:  Drugs       Date:  2008       Impact factor: 9.546

2.  The influences of cytokines as a possible substrate for the psychological effects of immunomodulation therapy in multiple sclerosis.

Authors:  N N Spirin; D S Kasatkin
Journal:  Neurosci Behav Physiol       Date:  2009-01

Review 3.  Clinical prognostic factors in multiple sclerosis: a natural history review.

Authors:  Alexandra Degenhardt; Sreeram V Ramagopalan; Antonio Scalfari; George C Ebers
Journal:  Nat Rev Neurol       Date:  2009-12       Impact factor: 42.937

4.  Impact of multiple sclerosis relapses on progression diminishes with time.

Authors:  H Tremlett; M Yousefi; V Devonshire; P Rieckmann; Y Zhao
Journal:  Neurology       Date:  2009-11-04       Impact factor: 9.910

5.  Examining the joint effect of disability, health behaviors, and comorbidity on mortality in MS.

Authors:  Amber Salter; Tuula Tyry; Guoqiao Wang; Robert J Fox; Gary Cutter; Ruth Ann Marrie
Journal:  Neurol Clin Pract       Date:  2016-10

Review 6.  Multiple sclerosis: it epidemiological, genetic, and health care impact.

Authors:  R Williams; A S Rigby; M Airey; M Robinson; H Ford
Journal:  J Epidemiol Community Health       Date:  1995-12       Impact factor: 3.710

7.  Obstetrical epidural and spinal anesthesia in multiple sclerosis.

Authors:  Ellen Lu; Yinshan Zhao; Leanne Dahlgren; Roanne Preston; Mia van der Kop; Anne Synnes; A Dessa Sadovnick; Anthony Traboulsee; Helen Tremlett
Journal:  J Neurol       Date:  2013-07-18       Impact factor: 4.849

8.  Long-Term Cost Effectiveness of Interferon-beta-1a in the Treatment of Relapsing-Remitting Multiple Sclerosis : An Econometric Model.

Authors:  Claude Lepen; Patricia Coyle; Timothy Vollmer; Lance Blumhardt; Hervé Lilliu; Ariel Beresniak
Journal:  Clin Drug Investig       Date:  2003       Impact factor: 2.859

9.  Analysis of Diagnoses Associated with Multiple Sclerosis-Related In-Hospital Mortality Using the Premier Hospital Database.

Authors:  Frank R Ernst; Jennifer Pocoski; Gary Cutter; David W Kaufman; Dirk Pleimes
Journal:  Int J MS Care       Date:  2016 May-Jun

10.  Birth hospitalization in mothers with multiple sclerosis and their newborns.

Authors:  Ellen Lu; Yinshan Zhao; Feng Zhu; Mia L van der Kop; Anne Synnes; Leanne Dahlgren; A Dessa Sadovnick; Ana-Luiza Sayao; Helen Tremlett
Journal:  Neurology       Date:  2013-01-09       Impact factor: 9.910

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.